articleNature MedicineAug 11, 2022HYBRID OA

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

MMMarta Milà‐AlomàNJNicholas J. AshtonMSMahnaz ShekariGSGemma SalvadóPOPaula Ortiz‐Romero

Universitat Pompeu Fabra · Instituto de Salud Carlos III · +21 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer's disease are needed to facilitate the initial screening process of participants in disease-modifying trials. Previous biofluid data suggest that phosphorylated tau231 (p-tau231) could indicate incipient Aβ pathology, but a comprehensive comparison with other putative blood biomarkers is lacking. In the ALFA+ cohort, all tested plasma biomarkers (p-tau181, p-tau217, p-tau231, GFAP, NfL and Aβ42/40) were significantly changed in preclinical Alzheimer's disease. However, plasma p-tau231 reached abnormal levels with the lowest Aβ burden. Plasma p-tau231 and p-tau217 had the strongest association with Aβ positron emission…

Citation impact

346
total citations
FWCI
40.17
Percentile
100%
References
33
Citations per year

Authors

21

Topics & keywords

Topics
Keywords
  • Medicine
  • Pathology
  • Disease
  • Positron emission tomography
  • Alzheimer's disease
  • Population
  • Amyloid (mycology)
  • Biomarker
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding